Plich Advisory is a top-tier boutique strategy & advisory firm for pharmaceutical leaders. We specialise in strategic positioning, pricing and commercialisation of medicines in Europe, USA and beyond. Our approach is wildly different and much quicker than other firms with incredible success rates! Working with Adam Plich, Managing Director, and our team clients are able to: 🔹Persuade BoD to speed up operations in EU to launch orphan cancer medicine with an upside potential of $90–130M over 5 years. 🔹Raise $84M with the long-term US & EU price forecast for an orphan medicine across 3 indications. 🔹Convince CEO to launch new indication based on new launch sequence of 2 products across 4 indications. 🔹Set pricing strategy for 5 orphan drugs in EU&US. 🔹 Refine the forecast for the DD for the acquisition of Established Brands facing generics (Gx). 🔹 Impact sales for several clients by $80–200M (each) for products facing loss of exclusivity (LoE). Imagine what results like this will mean for your company, your career and patients. Our key services are: ➡️ Pricing and Forecast Pressure-Test ➡️ Strategic Positioning and Value Proposition ➡️ European Strategy, International (US) Expansion, Go-To-Market models ➡️ Inlicensing/Outlicensing, M&A, Deal Advice and Partnering Support ➡️ Pricing & Market Access Strategy and Launch Plan ➡️ Trainings, Processes and Organisation Set-UP ➡️ LOSS OF EXCLUSIVITY Toolbox Many of our clients tell us that in addition to the quick bespoke advice and immediately actionable solutions, they see numerous long-term benefits from working with our experienced team: • They can achieve their objectives with a tremendous amount of confidence. • They are respected and seen as experts in the company and industry. • They are proud to create more access to patients. Are you looking for these results in your company? If so, call Plich Advisory today at +31 646 881 890 or email adam.plich@plichadvisory.com to schedule an immediate action review.